These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 11249763)

  • 1. Technology evaluation: AAV factor IX gene therapy, Avigen Inc.
    Fabb SA; Dickson JG
    Curr Opin Mol Ther; 2000 Oct; 2(5):601-6. PubMed ID: 11249763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
    Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW
    Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA
    Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
    Hasbrouck NC; High KA
    Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AAV vectors for hemophilia B gene therapy.
    Chao H; Walsh CE
    Mt Sinai J Med; 2004 Oct; 71(5):305-13. PubMed ID: 15543431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.
    Manno CS; Pierce GF; Arruda VR; Glader B; Ragni M; Rasko JJ; Ozelo MC; Hoots K; Blatt P; Konkle B; Dake M; Kaye R; Razavi M; Zajko A; Zehnder J; Rustagi PK; Nakai H; Chew A; Leonard D; Wright JF; Lessard RR; Sommer JM; Tigges M; Sabatino D; Luk A; Jiang H; Mingozzi F; Couto L; Ertl HC; High KA; Kay MA
    Nat Med; 2006 Mar; 12(3):342-7. PubMed ID: 16474400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy.
    Herzog RW; High KA
    Thromb Haemost; 1999 Aug; 82(2):540-6. PubMed ID: 10605748
    [No Abstract]   [Full Text] [Related]  

  • 12. Persistent expression of canine factor IX in hemophilia B canines.
    Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
    Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
    Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
    Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functions of AAV-CMV-F.IX And AAV-EF1alpha-F.IX in gene therapy for hemophilia B.
    Wiwanitkit V
    Hum Gene Ther; 2007 Feb; 18(2):89-92. PubMed ID: 17266422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.
    Snyder RO; Miao C; Meuse L; Tubb J; Donahue BA; Lin HF; Stafford DW; Patel S; Thompson AR; Nichols T; Read MS; Bellinger DA; Brinkhous KM; Kay MA
    Nat Med; 1999 Jan; 5(1):64-70. PubMed ID: 9883841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors.
    Couto LB
    Semin Thromb Hemost; 2004 Apr; 30(2):161-71. PubMed ID: 15118928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy. Side effects sideline hemophilia trial.
    Kaiser J
    Science; 2004 Jun; 304(5676):1423-5. PubMed ID: 15178771
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice.
    Kim HS; Kim JC; Lee YK; Kim JS; Park YS
    J Gene Med; 2011 Jul; 13(7-8):365-72. PubMed ID: 21710610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for hemophilia: clinical trials and technical tribulations.
    Viiala NO; Larsen SR; Rasko JE
    Semin Thromb Hemost; 2009 Feb; 35(1):81-92. PubMed ID: 19308896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for hemophilia.
    Ponder KP
    Curr Opin Hematol; 2006 Sep; 13(5):301-7. PubMed ID: 16888433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.